Wczytywanie kursów wyceny...
Prognoza
Nie mamy danych analityków dla tej spółki.
Wiadomości Przejdź do aktualności
Medacta grows in H1 2026, free cash flow turns negative
Medacta reported currency-adjusted revenue growth of around 10% in H1 2026 to EUR 368m and an adjusted EBITDA of EUR 97m (currency-adjusted margin 27.8%). Gross margin fell to 65.2% and free cash flow turned negative at -EUR 18.6m due to inventory build-up and investments; operating cash flow also declined. Management confirmed the full-year guidance (currency-adjusted revenue growth 10–14% and margin improvement) and expects improvement in H2 supported by a US recovery, shipments to India and easier comparables. The stock fell 3.43% and traded near its 52-week low as investors highlighted weaker cash generation and margin trends. » Więcej na de.investing.com
Medacta: significantly lower half-year profit despite stable operational performance
Medacta reports H1 2026 revenue of €368.0m (about +7%) and adjusted EBITDA of €97.4m (-1.4%); the margin fell to 26.5% from 28.7% a year earlier. Net profit declined to €41.9m, mainly because a one-off takeover gain from 2025 (Parcus Medical) did not recur. CEO Francesco Siccardi cited an unexpected slowdown in the US market and higher transport costs as headwinds; full-year targets remain confirmed with a revenue target of +10–14% and an adjusted EBITDA margin improvement of ~50 basis points, and medium-term annual revenue growth of 12–15% is targeted for 2024–2027. » Więcej na finanzen.net
Medacta misses revenue forecast – North America weaker growth
Medacta reports first-half group revenue of €368 million, which is 1% below analysts' expectations on a constant-currency basis (consensus €373 million). Constant-currency revenue growth was 9.7% versus an expected 11.5%, driven by strong gains in Asia‑Pacific (13.1%) and EMEA (10.0%), while North America grew only 6.6% on a constant-currency basis. Weaker performance was recorded in knee, spine, and shoulder and sports medicine; Medacta attributes the US slowdown in part to a sales reorganization in the spine division. The company confirms its full-year guidance of 10–14% constant-currency revenue growth and says it would need to achieve around 14.3% constant-currency growth in the second half to reach the midpoint. » Więcej na de.investing.com
Historyczne dywidendy Dywidendy
Wszystkie wskaźniki dywidendowe Wszystkie wskaźnikiDane finansowe spółki
| (EUR) | czerwiec 2026 | |
|---|---|---|
| Przychody | 366,4 mln | - |
| Zysk brutto | 239,02 mln | - |
| Zysk netto | 41,66 mln | - |
| EBITDA | 96,26 mln | - |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 2,4 mld € |
Liczba akcji | 19,93 mln |
Maksimum/minimum z 52 tygodni | 142,80 € - 101,38 € |
Stopa dywidendy | 0,98% |
Dywidendy TTM | 1,20 € |
Beta | 0,99 |
C/Z (PE Ratio) | 30,82 |
PEG (PEG Ratio) | -1,69 |
C/WK (PB Ratio) | 4,93 |
C/S (PS Ratio) | 3,38 |
Profil spółki
Medacta Group SA entwickelt, produziert und vertreibt orthopädische und neurochirurgische Medizinprodukte in Europa, Nordamerika, im asiatisch-pazifischen Raum und international. Das Unternehmen bietet personalisierte kinematische Modelle und 3D-Planungstools für die Bereiche Hüfte, Knie, Schulter, Sportmedizin und Wirbelsäule an. Das Unternehmen wurde 1958 gegründet und hat seinen Hauptsitz in Castel San Pietro, Schweiz.
| Nazwa | MEDACTA GROUP S.A. SF-,10 |
| CEO | Francesco Siccardi |
| Siedziba | Castel San Pietro,
ti Szwajcaria |
| Strona internetowa | |
| Sektor | Ochrona zdrowia |
| Branża | Technologie medyczne |
| Debiut giełdowy | 03.04.2019 |
| Pracownicy | 2165 |
Deep Dive
Symbole giełdowe
| Giełda | Symbol |
|---|---|
SIX | MOVE.SW |
London Stock Exchange | 0A05.L |
Pnk | MEDGF |
Düsseldorf | 6MD.DU |
London | 0A05.L |
München | 6MD.MU |